drugset
Drugs / ssCART-19
last change Dec 2025 re-read 2 minutes ago

ssCART-19

also known as U01

Cell therapy targets CD19

Developed for
B-cell acute lymphoblastic leukemia · acute lymphoblastic leukemia · B-cell adult acute lymphocytic leukemia · B-cell neoplasm · lymphoma
Investigated by
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · The First Affiliated Hospital of Soochow University · Peking University People's Hospital · Shanghai Tongji Hospital, Tongji University School of Medicine · The Second People's Hospital of Huai'an · Third Military Medical University

Trials 6 · a red edge is where a trial was stopped

today NCT06987916 · Ph 1/2 NCT07093073 · Ph 1 NCT06367114 · Ph 2 NCT03984968 · Ph 1/2 NCT03275493 · Ph 1/2 NCT03919240 · Ph 1/2
2016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07093073 Jan 2025 → Jan 2027 expected lymphoma Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Recruiting No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT06987916 Apr 2025 → Apr 2028 expected B-cell neoplasm Shanghai Tongji Hospital, Tongji University School of Medicine Recruiting No outcome recorded
Phase 1/2 NCT03984968 Jul 2017 → Jul 2025 overdue B-cell adult acute lymphocytic leukemia The First Affiliated Hospital of Soochow University Active not recruiting No outcome recorded
Phase 1/2 NCT03275493 Jul 2017 → Dec 2024 B-cell acute lymphoblastic leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Unknown No outcome recorded
Phase 1/2 NCT03919240 Dec 2015 → Aug 2027 expected B-cell acute lymphoblastic leukemia The First Affiliated Hospital of Soochow University Active not recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT06367114 Apr → Sep 2024 acute lymphoblastic leukemia Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as ssCAR-T-19 “We conducted a phase II clinical trial of ssCAR-T-19 cells, anti-CD19 CAR-T cells with shRNA targeting IL-6, in 61 patients with r/r B-ALL.” PMID 36105799 ↗ Aug 2022
6

“This study focused on the effects of the TB level on both the safety and efficacy of ssCART-19 as a treatment for r/r B-ALL.” PMID 35013456 ↗ Jan 2022

“shRNA-IL6-modified anti-CD19 CAR-T(ssCAR-T-19) therapy” PMID 32399214 ↗ May 2020

NCT06367114 ↗

NCT06987916 ↗

NCT07093073 ↗

NCT03984968 ↗
Known as U01 “Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma” NCT07093073 ↗
Action Inhibit “to silence the IL-6 gene” NCT06987916 ↗
Modality Cell therapy “anti-CD19 CAR-T cells with shRNA targeting IL-6” PMID 36105799 ↗ Aug 2022
Route Other “receive infusion of CD19-targeting CART-cells” NCT03919240 ↗
Target CD19 “anti-CD19 CAR-T cells with shRNA targeting IL-6” PMID 36105799 ↗ Aug 2022